DEFA14A ·Filed Apr 30, 2026

IMA

ImageneBio, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001140361-26-018272
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for the definitive proxy statement (DEF 14A) which should contain specific vote items and management proposals. The DEFA14A itself is a procedural solicitation filing with no standalone trading signal.

DirectionNeutral
Confidencelow
Horizondays
Final — all horizons settled through T+60d
IMA ▲ +1.77% at T+60d
NEUTRAL call ✓ call won +1.77% · α vs SPY -1.30% · entry $5.66 → $5.76
Entry anchored
Apr 30, 2026
via day open
T+1d
+0.97%
call +0.97% · α +1.31%
$5.72
settled 5mo ago
T+5d
-6.54%
call -6.54% · α -8.88%
$5.29
settled 5mo ago
T+20d
-3.36%
call -3.36% · α -8.62%
$5.47
settled 4mo ago
T+60d
+1.77%
call +1.77% · α -1.30%
$5.76
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

ImageneBio filed a DEFA14A (definitive additional proxy soliciting materials) on April 30, 2026. The filing is marked as filed by the registrant and checks the box for 'Definitive Additional Materials' and 'Soliciting Material Pursuant to 240.14a-12', indicating management is actively soliciting shareholder votes. The document content is largely boilerplate and contains no specific financial figures, vote details, or activist demands.

Key Facts

  • Filed DEFA14A on 2026-04-30 as definitive additional proxy soliciting materials
  • Filed by the registrant (management), not a dissident party
  • Document text is largely boilerplate with no specific financial data, vote items, or activist demands
  • Company has a $63M market cap and 71% analyst bullish consensus
  • Historical performance shows 0% win rate at T+20 across 2 settled reports with avg -14.89% return

Financial Impact

No financial figures disclosed in the filing

Risk Factors

  • No substantive financial or voting details in this filing
  • Historical poor performance on IMA filings suggests limited predictive value

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
71% bullish (7 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001140361-26-018272
Document: 0001140361-26-018272-index-headers.html0001140361-26-018272
Document: 0001140361-26-018272-index.html0001140361-26-018272
Document: 0001140361-26-018272.txt0001140361-26-018272
8 reports for IMA
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+20▲ +14.76%Aug 7, 2026
Filters
Rows
Reports for IMA — sortable, filterable
TypeNow
Aug 7, 2026
8w ago
EFFECT
BEARISH ★ 5/10
$5.69 $4.85▲ +14.76%▲ +14.37%$4.60 (+19.16%)
Jun 26, 2026
14w ago
8-K
NEUTRAL ★ 3/10
$6.07 $5.59▼ −7.91%▼ −7.63%$4.60 (−24.22%)
Apr 30, 2026
22w ago
DEFA14A
NEUTRAL ★ 3/10
$5.66 $5.47▼ −3.36%▼ −8.62%$4.60 (−18.73%)
Apr 13, 2026
24w ago
8-K
BEARISH ★ 6/10
$6.05 $5.61▲ +7.27%▲ +15.00%$4.60 (+23.97%)
Apr 13, 2026
24w ago
Press Release
BEARISH ★ 6/10
$6.05 $5.61▲ +7.27%▲ +15.00%$4.60 (+23.97%)
Apr 6, 2026
25w ago
EFFECT
NEUTRAL ★ 3/10
$4.55 $5.72▲ +25.60%▲ +16.62%$4.60 (+1.10%)
Mar 17, 2026
28w ago
Press Release
NEUTRAL ★ 3/10
$5.83 $5.78▼ −0.77%▼ −6.82%$4.60 (−21.03%)
Mar 10, 2026
29w ago
Press Release
NEUTRAL ★ 4/10
$6.07 $4.57▼ −24.71%▼ −24.56%$4.60 (−24.22%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (64h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access